Inactivated hepatitis A vaccine,
does it really help with Prevention of symptomatic hepatitis A in nonimmune children and high-risk adults?
research showsInactivated hepatitis A vaccine is rated A because it directly prevents symptomatic hepatitis A in nonimmune people. In a placebo-controlled community trial in New York, no clinical hepatitis A occurred in the vaccine group versus 25 cases in the placebo group during the efficacy period among 1,037 seronegative children. In a cluster-randomized double-blind trial involving 40,119 Thai schoolchildren, protective efficacy after two doses was 94%. The endpoint was clinical disease confirmed by symptoms, liver-enzyme elevation, and IgM rather than antibody titer alone, and the result was reproduced with different vaccines in different settings. Large direct efficacy trials were concentrated in children, however, so application to high-risk adults also draws on adult immunogenicity, accumulated effectiveness evidence, and guidelines; duration of protection and booster needs must be separated by product, age, and immune status.
ads claimPromotion can turn high efficacy during the trial period into a claim of 100% lifelong protection after one injection. The required number and spacing of doses vary by age and product, immune responses can be lower in immunocompromised people, and the vaccine does not treat established infection.
Useful facts when choosing a product
- An inactivated vaccine contains no replication-competent hepatitis A virus and therefore cannot cause hepatitis A.
- It is administered intramuscularly, and the licensed age, number of primary doses, and interval must follow the selected product label and national schedule.
- Injection-site pain or redness, headache, and transient fatigue are common, whereas serious allergic reactions are very rare.
- During immunosuppression, reduced immune response rather than vaccine infection is the main concern, so timing and additional management may require clinical advice.
What the research actually shows
Werzberger randomized seronegative children aged 2 to 16 years in a repeatedly affected community in Monroe, New York, to inactivated vaccine or placebo. During a mean follow-up of 103 days, 25 placebo recipients and no vaccine recipients developed disease meeting the symptom, hepatitis A IgM, and alanine aminotransferase definition from day 50 onward. Innis cluster-randomized 40,119 children in 148 Thai primary schools to hepatitis A vaccine or hepatitis B control vaccine. Thirty-eight of 40 clinical hepatitis A cases under surveillance occurred in controls; efficacy was 94% in the two-dose period and 95% cumulatively. The 2022 WHO position paper integrates these direct trials with durability evidence, but regulatory or guideline endorsement was not substituted for trial evidence in the grade.
Why this is classified as A (91)
Randomized double-blind field trials in 1,037 and 40,119 participants reduced directly measured symptomatic hepatitis A by 94% to 100% in different settings. This is not surrogate-only evidence, and the effect size and consistency support A. Because the pivotal trials centered on children, involved vaccine manufacturers, and leave less direct evidence for high-risk adults, durability, and boosters, the composite claim is adjusted to A with 91 points.
Counterpoint. People who are already immune have little additional benefit, and the value of prevaccination serology depends on local epidemiology, age, exposure risk, and cost. After a recent exposure, vaccine or immune globulin should be selected promptly according to timing, age, and underlying disease.
Rejudgment record. Cross-check revision — Applied A because two independent large randomized double-blind field trials reduced the direct clinical endpoint of symptomatic hepatitis A in seronegative children by 94% to 100%, with consistency across vaccines and settings
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of symptomatic hepatitis A in nonimmune people | A | Clinical disease itself was reduced by 94% to 100% in two large randomized field trials in different settings. |
| Prevention of symptomatic hepatitis A in seronegative children | A | Direct support comes from a 1,037-child placebo-controlled trial and a 40,119-child active-controlled cluster trial. |
| Prevention of symptomatic hepatitis A in nonimmune high-risk adults | B | Adult immunogenicity, effectiveness, and guidelines are consistent, but no adult clinical-endpoint trial matches the scale of the pediatric field trials. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Werzberger A et al. 1992 | Randomized double-blind placebo-controlled community efficacy trial | 518 | Multicenter vaccine-development study with manufacturer involvement | Clinical hepatitis A confirmed by symptoms, hepatitis A IgM, and alanine aminotransferase elevation | From day 50 onward, 25 cases occurred with placebo and none with vaccine, for 100% efficacy (p<0.001). | Core randomized evidence with a direct clinical endpoint |
| Innis BL et al. 1994 | School-cluster randomized double-blind active-controlled field trial | 40,119 | Collaboration among military and public research institutions and the vaccine developer | Hepatitis A detected through absence surveillance and confirmed by symptoms, alanine aminotransferase, and hepatitis A IgM | Protective efficacy was 94% after two doses (95% CI 79% to 99%) and 95% cumulatively (95% CI 82% to 99%). | Very large replication of direct preventive efficacy |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Inactivated hepatitis A vaccine x prevention of symptomatic hepatitis A — Evidence Grade A·91. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/inactivated-hepatitis-a-vaccine-symptomatic-hepatitis-a-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.